ClinicalTrials.gg
Sign In
RecruitingNCT07921810Updated Nov 6, 2026

Improving Morning Strength and Cognitive Performance Using Caffeine or Whole-body Vibration.

A Phase 4 interventional study of Caffeine (300mg) and whole-body vibration in Vibration Therapy, Caffeine and Control Condition, sponsored by Liverpool John Moores University. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by Liverpool John Moores University · Phase 4, Interventional, and Other

Updated Nov 6, 2026Newly registeredGo to Updates ↓
Phase
Phase 4
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
18 Years to 35 Years
Sex
All
01

Study summary

Improving morning strength and cognitive performance using caffeine or whole-body vibration.

02

Conditions studied

  • Vibration Therapy
  • Caffeine
  • Control Condition
  • Placebo - Control
03

In context

Lead sponsor

Liverpool John Moores University is the lead sponsor of 75 studies on the registry; 13 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 35 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age: 18-35years old
  • Healthy (as determined by the pre-participation questionnaire)
  • >2 years strength trained individuals
  • Consume >150 mg/day of caffeine
  • Be able to stick to the retiring and waking schedule of the study as well as no exercise 24 h before and no caffeine.

Exclusion criteria

Exclusion Criteria:

  • Age: \<18 or >35 years old
  • Consume \<150 mg/day of caffeine
  • Deemed unhealthy/unable to perform exercise determined by PAR-Q
  • Shift worker or having travelled out of the UK time zone within the last month of testing
  • Muscle related injury or broken/fractured bone within the past 3 years Diagnosed sleep disorder
05

Study design

Phase
Phase 4
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    ABCD

    Control, Placebo, Caffeine, WBV

    Drug: Caffeine (300mg) · Device: whole-body vibration · Dietary Supplement: Placebo · Behavioral: Control

  • Experimental
    BCDA

    Placebo, Caffeine, WBV, Control

    Drug: Caffeine (300mg) · Device: whole-body vibration · Dietary Supplement: Placebo · Behavioral: Control

  • Experimental
    CDAB

    Caffeine, WBV, Control, Placebo

    Drug: Caffeine (300mg) · Device: whole-body vibration · Dietary Supplement: Placebo · Behavioral: Control

  • Experimental
    DABC

    WBV, Control, Placebo, Caffeine

    Drug: Caffeine (300mg) · Device: whole-body vibration · Dietary Supplement: Placebo · Behavioral: Control

Interventions

  • DrugCaffeine (300mg)

    Caffeine (300mg; 3x 100mg)

  • Devicewhole-body vibration

    15 min of WBV at 60 Hz

  • Dietary supplementPlacebo

    1.6 mg Maltodextrin

  • BehavioralControl

    no-pill control

06

What researchers measure

Primary outcomes

  1. Bench press and back squat Peak VELOCITY

    Highest velocity of production

    Time frame: around 4 weeks from the 1st to the last session

  2. Peak Torque MVC

    Highest torque exerted during trial

    Time frame: around 4 weeks from the 1st to the last session

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Mar 2027, 4 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 6, 2026
StartEst.
Nov 1, 2026
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07921810
Lead sponsor
Liverpool John Moores University
Responsible party
Joao Pedro Saes Agulhari (Postgraduate RESEARCHER, Liverpool John Moores University) — Principal investigator
First posted
Nov 6, 2026
Start date
Nov 1, 2026 (estimated)
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Joao Agulhari, BSc
Contact
jpagulhari@gmail.com
07379664724
Ben J Edwards, PhD
Contact
B.J.Edwards@ljmu.ac.uk
01519046238
Joao PS Agulhari, BSc
principal investigator · Liverpool John Moores University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

Liverpool John Moores University

Start the discussion